Gene Expression Scoring for Tuberculosis Therapy Duration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective biomarkers for determining the optimal duration of tuberculosis therapy, particularly for multidrug-resistant TB, leading to variable treatment outcomes and potential development of drug resistance.
Innovation Solution
A method involving the determination of specific gene expression levels, such as CD274, FAM20A, GYG1, HIST1H1B, LPCAT2, RPAP3, A_33_P3281041, BATF2, C2, IFIT2, IFITM1, KREMEN1, and PDE4D, to calculate scores and values that predict treatment outcomes and therapy completion, allowing for personalized treatment duration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standardized treatment duration (e.g., 20 months for MDR-TB) is applied to all patients, then treatment coverage is ensured, but individual optimal therapy duration cannot be determined leading to variable outcomes and drug resistance
Solution Approach 1:
The invention changes the parameter of therapy duration from a fixed standardized value to a variable determined by gene expression profiles. By measuring expression levels of specific genes (e.g., CD274, IFITM1, BATF2) and calculating composite scores, the treatment duration is dynamically adjusted to match individual patient responses, thereby achieving both reliability through objective biomarkers and adaptability through personalized timing.
Solution Approach 2:
The invention replaces the mechanical/time-based standardized treatment schedule with a biological marker-based decision system. Instead of following fixed calendar-based protocols, clinicians use gene expression measurements and calculated scores to determine when therapy should end, substituting biological information processing for mechanical time-based protocols.
2Reliability
If treatment duration is extended to ensure cure, then relapse-free outcome improves, but development of drug resistance and severe adverse events increase
Solution Approach 1:
The invention implements feedback by continuously monitoring gene expression levels during treatment and using these measurements to determine the optimal endpoint. The system provides real-time biological feedback about treatment response, allowing clinicians to extend therapy only as long as necessary to achieve cure, thereby preventing both under-treatment (relapse) and over-treatment (resistance and adverse events).
Solution Approach 2:
The invention performs preliminary assessment of gene expression profiles at baseline and during treatment to predict and determine the optimal therapy duration in advance. By evaluating biomarkers early in the treatment course, the system can forecast the required treatment duration and prevent unnecessary extension that would lead to drug resistance and adverse events.
3Measurement precision
If gene expression analysis is performed to determine individualized therapy duration, then treatment precision improves, but diagnostic complexity and resource requirements increase
Solution Approach 1:
The invention extracts only the most relevant gene expression markers from the complex genome that are specifically associated with treatment response and duration determination. By focusing on a targeted panel of genes (such as CD274, IFITM1, BATF2, GBP5) rather than analyzing the entire transcriptome, the system achieves high measurement precision while reducing diagnostic complexity and resource requirements.
Solution Approach 2:
The invention segments the complex task of determining therapy duration into discrete measurable components: specific gene expression levels, intermediate score calculations, and final duration prediction. This segmentation allows the complex diagnostic process to be broken down into manageable steps that can be performed with standardized assays and computational algorithms, reducing overall system complexity.
Data Source
AI summary
The present invention relates in a first aspect to a method for diagnosing tuberculosis infection calculating a score based on the expression of a predetermined set of genes and as well as diagnosing or predicting the clinical outcome of the tuberculosis infection based on said score. In another aspect, a method for treatment monitoring and determining treatment duration in an individual with tuberculosis infection is provided. Said method includes the determination of the expression level of predetermined genes, calculating a value based thereon and the therapy monitoring or treatment monitoring and determining treatment duration in said individual accordingly. Moreover, a method for determining the therapy-end of a treatment of tuberculosis infection in an individual affected with tuberculosis infection is provided. Said method includes the consideration of the expression level of predetermined genes together with the scores and values identified and calculating whether therapy is completed or not based on the value, the score and the expression level of said predetermined genes accordingly. In a further aspect, the use of a test kit or the use of kits of parts for conducting the methods according to the present invention is provided. Further, an array comprising means for detecting the expression of predetermined genes is identified as well as the use of the same. Moreover, a computer implemented method is provided as well as a computer readable medium or computer program product having computer executable instructions for performing the steps of the method disclosed herein.